JPMorgan Chase & Co. Boosts Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

JPMorgan Chase & Co. lifted its holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 75.7% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 859,710 shares of the company's stock after acquiring an additional 370,511 shares during the quarter. JPMorgan Chase & Co. owned 1.21% of Zentalis Pharmaceuticals worth $2,605,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in the business. Prudential Financial Inc. bought a new stake in Zentalis Pharmaceuticals in the fourth quarter worth $39,000. Sei Investments Co. bought a new stake in shares of Zentalis Pharmaceuticals in the 4th quarter valued at about $107,000. Virtu Financial LLC bought a new stake in shares of Zentalis Pharmaceuticals in the 4th quarter valued at about $76,000. Thrivent Financial for Lutherans boosted its holdings in Zentalis Pharmaceuticals by 155.9% during the 4th quarter. Thrivent Financial for Lutherans now owns 70,641 shares of the company's stock valued at $214,000 after acquiring an additional 43,036 shares during the period. Finally, Primecap Management Co. CA grew its position in Zentalis Pharmaceuticals by 1.5% during the 4th quarter. Primecap Management Co. CA now owns 1,520,630 shares of the company's stock worth $4,608,000 after acquiring an additional 22,600 shares during the last quarter.

Insider Transactions at Zentalis Pharmaceuticals

In other Zentalis Pharmaceuticals news, Director Jan Skvarka purchased 60,000 shares of the stock in a transaction that occurred on Friday, January 31st. The stock was bought at an average cost of $1.72 per share, with a total value of $103,200.00. Following the transaction, the director now directly owns 149,551 shares in the company, valued at approximately $257,227.72. The trade was a 67.00 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Ingmar Bruns acquired 20,000 shares of the company's stock in a transaction that occurred on Thursday, February 6th. The shares were acquired at an average cost of $2.28 per share, for a total transaction of $45,600.00. Following the purchase, the insider now directly owns 36,629 shares of the company's stock, valued at $83,514.12. This represents a 120.27 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 3.60% of the company's stock.

Zentalis Pharmaceuticals Trading Up 8.1 %

Shares of NASDAQ ZNTL opened at $1.47 on Wednesday. The firm has a fifty day simple moving average of $1.72 and a two-hundred day simple moving average of $2.54. The firm has a market capitalization of $105.56 million, a PE ratio of -0.59 and a beta of 1.80. Zentalis Pharmaceuticals, Inc. has a 12 month low of $1.01 and a 12 month high of $13.46.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last released its quarterly earnings results on Wednesday, March 26th. The company reported ($0.66) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.75) by $0.09. The company had revenue of $26.90 million during the quarter. On average, sell-side analysts predict that Zentalis Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have weighed in on the company. Wells Fargo & Company lowered their price objective on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an "equal weight" rating for the company in a research report on Thursday, January 30th. Wedbush reissued a "neutral" rating and set a $4.00 price target on shares of Zentalis Pharmaceuticals in a research report on Friday, March 28th. HC Wainwright restated a "buy" rating and issued a $10.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Thursday, March 27th. Finally, UBS Group lowered their price objective on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a "neutral" rating for the company in a research note on Tuesday, January 28th. Five analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat, Zentalis Pharmaceuticals presently has an average rating of "Hold" and a consensus target price of $8.24.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.

Want to see what other hedge funds are holding ZNTL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.